F
Francis Giles
Researcher at University of Texas MD Anderson Cancer Center
Publications - 18
Citations - 1599
Francis Giles is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 18, co-authored 18 publications receiving 1515 citations.
Papers
More filters
Journal ArticleDOI
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Hagop Kantarjian,Susan O'Brien,Jorge Cortes,Francis Giles,Stefan Faderl,Elias Jabbour,Guillermo Garcia-Manero,William Wierda,R N Sherry Pierce,Jianqin Shan,Elihu Estey +10 more
TL;DR: The aim was to develop prognostic models for complete response (CR), induction (8‐week) mortality, and survival rates in elderly AML, which would be used to advise oncologists and patients of expectations with standard AML type therapy, and to establish baseline therapy results against which novel strategies would be evaluated.
Journal ArticleDOI
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Thomas B. Sneed,Hagop Kantarjian,Moshe Talpaz,Susan O'Brien,R N Mary Beth Rios,B. Nebiyou Bekele,Xian Zhou,R N Debra Resta,William G. Wierda,Stefan Faderl,Francis Giles,Jorge E. Cortes +11 more
TL;DR: During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of therapy and/or dose reductions.
Journal ArticleDOI
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders†
Jorge Cortes,Francis Giles,Susan O'Brien,Deborah Thomas,Maher Albitar,Mary Beth Rios,Moshe Talpaz,Guillermo Garcia-Manero,Stefan Faderl,Laurie Letvak,August Salvado,Hagop Kantarjian +11 more
TL;DR: Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R) that is implicated in the pathogenesis of myeloproliferative disorders (MPD).
Journal ArticleDOI
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Hagop Kantarjian,Miloslav Beran,Jorge Cortes,Susan O'Brien,Francis Giles,R N Sherry Pierce,Jianqin Shan,William Plunkett,Michael Keating,Elihu Estey +9 more
TL;DR: The aim of this study was to analyze the long‐term results with topotecan‐cytarabine versus other intensive chemotherapy regimens in higher‐risk MDS.
Journal ArticleDOI
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Jorge Cortes,Moshe Talpaz,Susan O'Brien,Francis Giles,R N Mary Beth Rios,J. Shan,Stefan Faderl,Guillermo Garcia-Manero,Alessandra Ferrajoli,William G. Wierda,Hagop Kantarjian +10 more
TL;DR: The availability of imatinib mesylate, a selective, Bcr‐Abl‐targeted therapy that is administered orally with minimal side effects, may clarify whether older age would remain an adverse factor (thus, implying a different age‐related CML biology).